The outcomes evaluated were: (i) changes in RA disease activity (through the monitoring of 16 RA markers); (ii) inflammation (measuring CRP, IL-1, IL-6, TNF-alpha and LTB4); (iii) risk for CVD (assessing CVD-related risk factors, such as TG, TC, LDL and HDL). The gene discussed is CRP; the disease is rheumatoid arthritis.